CD8A and Hepatitis: In this study, ILIB was used in the regions of the cubital vessels, liver and thymus, showing a reduction in the signs and symptoms of PLWHA and hepatitis, an increase in the counts of T-CD4+ lymphocytes (LT-CD4+), T-CD8+ lymphocytes (LT-CD8+), and total lymphocytes and a decrease in VL in participants with HIV infection(17).